• News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • Subscribe newsletter
  • Search
  • Menu Menu
International Hospital
  • AI
  • Cardiology
  • Oncology
  • Neurology
  • Genetics
  • Orthopaedics
  • Research
  • Surgery
  • Innovation
  • Medical Imaging
  • MedTech
  • Obs-Gyn
  • Paediatrics

Archive for category: E-News

E-News

Agfa HealthCare collaborates with IBM and Watson to advance cognitive imaging

, 26 August 2020/in E-News /by 3wmedia

Agfa HealthCare has joined the Watson Health medical imaging collaborative, a global initiative comprised of more than fifteen leading health systems, academic medical centres, ambulatory radiology providers and imaging technology companies. The collaborative aims to bring cognitive imaging into daily practice to help doctors address breast, lung, and other cancers; diabetes; eye health; brain disease; and heart disease and related conditions, such as stroke.
Members of the collaborative plan to put Watson to work to extract insights from previously invisible’ unstructured imaging data and combine that with a broad variety of data from other sources. In doing so, the efforts may help physicians make personalized care decisions relevant to a specific patient while building a body of knowledge to benefit broader patient populations. This information may include data from electronic health records, radiology and pathology reports, lab results, doctors’ progress notes, medical journals, clinical care guidelines and published outcomes studies.
Initial plans include training Watson and evaluating potential new offerings in a variety of patient care environments ranging from stand-alone ambulatory settings to integrated health delivery networks. The aim in doing so is to gather data based on diverse real-world experience and to share findings to inform how the medical community might reduce operational and financial inefficiencies, improve physician workflows, and adopt a patient-focused approach to improving patient care and outcomes.
‘With an ability to draw insights from massive volumes of integrated structured and unstructured data sources, cognitive computing could transform how clinicians diagnose, treat and monitor patients,’ said Anne Le Grand, vice president of Imaging for Watson Health. ‘Through IBMs medical imaging collaborative, Watson may create opportunities for radiologists to extract greater insights and value from imaging data while better managing costs.’
James Jay, Vice President Imaging IT and Integrated Care Solutions businesses at Agfa HealthCare, elaborates: ‘We are very excited about the opportunity to collaborate with IBM and Watson. Healthcare systems are under enormous pressure to improve productivity; our combined expertise has the capability to harness the untapped power of technology to deliver the gains that have so far only been achieved in isolated use cases. Together we will look for ways to advance our customers’ ability to leverage the analytics power of Watson united with our own Enterprise Imaging platform, to assure that the right knowledge is available, at the right time, to help diagnose and treat their patients. We will be diving into specific use cases to turn the power of big data into real, tangible applications focused on specific improvements in either speed or accuracy of decisions.’
Watson is the first commercially available cognitive computing capability representing a new era in computing. The system, delivered through the cloud, analyses high volumes of data, understands complex questions posed in natural language, and proposes evidence-based answers. Watson continuously learns, gaining in value and knowledge over time, from previous interactions. In April 2015, the company launched IBM Watson Health and the Watson Health Cloud platform. The new unit will help improve the ability of doctors, researchers and insurers to innovate by surfacing insights from the massive amount of personal health data being created and shared daily. The Watson Health Cloud allows this information to be de-identified, shared and combined with a dynamic and constantly growing aggregated view of clinical, research and social health data.

http://tinyurl.com/hxnrlns

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:38:032020-08-26 14:38:11Agfa HealthCare collaborates with IBM and Watson to advance cognitive imaging

Detecting blood alcohol content with an electronic skin patch

, 26 August 2020/in E-News /by 3wmedia

Overconsumption of alcohol can lead to errors in judgment, causing, for example, some people to get behind the wheel when they are impaired. To help imbibers easily and quickly know when they’ve had enough, scientists have developed a flexible, wearable patch that can detect a person’s blood-alcohol level from his or her sweat. The monitor works quickly and can send results wirelessly to a smartphone or other device.

In the U.S., one person dies every 53 minutes in an alcohol-related car accident, according to the Centers for Disease Control and Prevention. Currently, ignition interlock devices are being marketed as a way to prevent drunk drivers from starting a car engine. But these are based on breath analysis, which can be affected by a number of factors including humidity, temperature and whether someone has used mouthwash. Recent research has demonstrated that sweat can be a more reliable real-time indicator of blood alcohol content. At least two transdermal sensors have been developed to measure alcohol levels in sweat, but users have to wait up to 2 hours for results. Joseph Wang, Patrick Mercier and colleagues at the University of California, San Diego, set out to make a more practical version.

With temporary-tattoo paper, the researchers developed a patch that tests blood alcohol content non-invasively in three rapid steps. It induces sweat by delivering a small amount of the drug pilocarpine across the skin. An enzymatic reaction leads to the electrochemical detection of the alcohol content. And a flexible electronic circuit board transmits the data via a Bluetooth connection to a mobile device or laptop. The steps take less than 8 minutes from start to finish. In addition to connecting to vehicles’ ignition interlock systems, the sensor could be a simple tool for bartenders, friends or law enforcement to use, the researchers say.

American Chemical Society www.acs.org/content/acs/en/pressroom/presspacs/2016/acs-presspac-august-3-2016/detecting-blood-alcohol-content-with-an-electronic-skin-patch.html

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:38:032020-08-26 14:38:19Detecting blood alcohol content with an electronic skin patch

Effectiveness of text message-based remote monitoring for postpartum hypertension

, 26 August 2020/in E-News /by 3wmedia

Preeclampsia – the onset of high blood pressure resulting from pregnancy – is a leading cause of death and complications for women in the days following childbirth and discharge from the hospital. The sooner the doctors can detect the condition getting worse after delivery, the greater the chance there is of successful treatment with medication. However, since there is currently no effective way of predicting who is at-risk for increasing blood pressure, by the time worsening conditions are identified, patients often require more intensive care.
Recent ACOG guidelines recommend blood pressure monitoring via routine follow-up office visits within 72 hours of discharge and again at seven to ten days after childbirth. However, as many as 70 percent of patients do not attend these first follow-up appointments. With this in mind, and based on data showing that young women have high rates of cell phone use and text messaging, the Penn team hoped to determine whether implementing a remote blood pressure monitoring system for patients diagnosed with preeclampsia would allow them to identify advanced cases and intervene before hospital readmission is necessary.
‘Platforms that take advantage of telemedicine technology allow clinical care teams to evaluate, diagnose and treat patients remotely, and have been well established as an effective means of delivering care across a variety of specialties,’ said lead author Adi Hirshberg, MD, a fellow in the department of Obstetricics and Gynecology at the Hospital of the University of Pennsylvania. ‘By monitoring blood pressure levels for our postpartum patients who are at home with new babies and can’t always get to office visits, we can provide a convenient and effective way of identifying those who are at risk for complications and may require follow-up care before the situation becomes critical.’
In the study, 32 patients previously diagnosed with preeclampsia were given blood pressure cuffs when discharged from the hospital after childbirth. For seven days following discharge, text messages were sent reminding patients to take a daily blood pressure reading and send the results to their care provider. Patients whose blood pressure was high were then asked to take additional readings. Eighty four percent of participants reported a blood pressure reading within 24 or 48 hours of discharge, and 65 percent continued reporting test results for at least five of the seven days. As a result of the reports, two patients were identified as having elevated blood pressure and were put on oral medications, but none of the participants required readmission to the hospital.
‘Our results show that remote blood pressure monitoring via text messaging is an effective, convenient and patient-centred way of identifying patients who could be at risk of developing potentially life-threatening complications related to the condition,’ said senior author Sindhu Srinivas, MD, MSCE, director of Obstetrical Services at the Hospital of the University of Pennsylvania.

Perelman School of Medicinehttp://tinyurl.com/j6xkp3q

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:38:032020-08-26 14:38:26Effectiveness of text message-based remote monitoring for postpartum hypertension

New microscopy may identify best sperm cells

, 26 August 2020/in E-News /by 3wmedia

TAU researcher’s cutting-edge innovation pinpoints top candidates for assisted reproductive technology. More than 10percent of American women aged 15-44 struggle to conceive or maintain full-term pregnancies, according to the Centers for Disease Control and Prevention (CDC). Assisted reproductive technology (ART), through which eggs are fertilized with sperm in a lab and then returned to a woman’s uterus, is often the last resort for reproductively-challenged couples. But the physical, emotional, and financial toll they exact is high because the success rates of ART treatments are low – only 20-30percent, according to the CDC.
New microscopic technology from Tel Aviv University promises to be a game-changer in the field of reproductive assistance. A team of TAU scientists have devised a new method of microscopy allowing scientists to perform clinical sperm analysis without the use of staining, which can affect the viability of sperm samples.
Sperm cells are nearly transparent under standard microscopy methods. Their optical properties differ only slightly from those of their surroundings, resulting in a weak image contrast. Sperm cells cannot be stained, if fertilization is the goal, because the process might damage the resulting fetuses. The challenge is to pinpoint strong sperm candidates without staining, while still being able to characterize their viability.
The research was led by Dr. Natan Shaked, PhD, of the Department of Biomedical Engineering at TAU’s Faculty of Engineering and his masters student, Dr. Miki Hifler, MD. Sperm cells for the study were obtained from the Male Fertility Clinic at Chaim Sheba Medical Center in Israel.
There are two effective ART methods available today. The first is in vitro fertilization (IVF), in which a woman is treated with drugs that cause her ovaries to produce multiple eggs. These are placed in a Petri dish with a man’s sperm for fertilization for three to five days, then implanted in the woman’s uterus. The second is intracytoplasmic sperm injection (ICSI), in which a single sperm is injected into a mature egg and then transferred to a woman’s uterus. Dr. Shaked’s method is applicable to both methods, but is especially helpful in ICSI.
‘Until now, clinicians have chosen the best’ sperm according to their speed, but speed is not necessarily an indicator of DNA quality,’ Dr. Shaked says. ‘Some of the best sperm candidates are slow or even immobile because their tails have malfunctioned. If we can better determine the full structure and composition of the sperm, the success rate of ART treatments will be higher. Success means more births without congenital defects. In cases where sample staining is impossible – such as in vitro fertilization and ICSI – our device provides a promising new direction.’
His new device, a small ‘black box’ attached to an existing microscope, is smaller, cost-effective, and easier to align than conventional interferometric imaging methods. It is joined to new automated software that produces a thickness map of the sample and other physical parameters to evaluate the sperm’s viability in real time.
Dr. Shaked believes his new imaging process, which harnesses phase imaging methods to record the passage of light through a sample to assess its thickness, can quantify the quality of sperm used in ART, leading to more successful ART treatments.

American Friends of Tel Aviv University http://tinyurl.com/h5665oc

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:38:032020-08-26 14:38:05New microscopy may identify best sperm cells

Taking antidepressants during pregnancy increases risk of autism by 87%

, 26 August 2020/in E-News /by 3wmedia

Using antidepressants during pregnancy greatly increases the risk of autism, Professor Anick Berard of the University of Montreal and its affiliated CHU Sainte-Justine children’s hospital revealed. Prof. Berard, an internationally renowned expert in the fields of pharmaceutical safety during pregnancy, came to her conclusions after reviewing data covering 145,456 pregnancies. ‘The variety of causes of autism remain unclear, but studies have shown that both genetics and environment can play a role,’ she explained. ‘Our study has established that taking antidepressants during the second or third trimester of pregnancy almost doubles the risk that the child will be diagnosed with autism by age 7, especially if the mother takes selective serotonin reuptake inhibitors, often known by its acronym SSRIs.’
Berard and her colleagues worked with data from the Quebec Pregnancy Cohort and studied 145,456 children between the time of their conception up to age ten. In addition to information about the mother’s use of antidepressants and the child’s eventual diagnosis of autism, the data included a wealth of details that enabled the team to tease out the specific impact of the antidepressant drugs. For example, some people are genetically predisposed to autism (i.e., a family history of it.) Maternal age, and depression are known to be associated with the development of autism, as are certain socio-economic factors such as being exposed to poverty, and the team was able to take all of these into consideration.
‘We defined exposure to antidepressants as the mother having had one or more prescription for antidepressants filled during the second or third trimester of the pregnancy. This period was chosen as the infant’s critical brain development occurs during this time,’ Prof. Berard said. ‘Amongst all the children in the study, we then identified which children had been diagnosed with a form of autism by looking at hospital records indicating diagnosed childhood autism, atypical autism, Asperger’s syndrome, or a pervasive developmental disorder.
Finally, we looked for a statistical association between the two groups, and found a very significant one: an 87% increased risk.’ The results remained unchanged when only considering children who had been diagnosed by specialists such as psychiatrists and neurologists.
The findings are hugely important as six to ten percent of pregnant women are currently being treated for depression with antidepressants.

University of Montreal http://tinyurl.com/zgflp3h

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:38:032020-08-26 14:38:14Taking antidepressants during pregnancy increases risk of autism by 87%

New treatment to prevent nausea, vomiting caused by chemotherapy

, 26 August 2020/in E-News /by 3wmedia

A drug that blocks neurotransmitters could reduce nausea and vomiting caused by chemotherapy, research co-authored by a Sanford Health physician and published in the New England Journal of Medicine finds.
Sanford oncologist and cancer researcher Steven Powell, M.D., was among a team of researchers who discovered that the drug olanzapine, which is FDA approved for use as an antipsychotic agent, significantly improved nausea prevention in patients who were receiving chemotherapy for cancer treatment. The drug blocks neurotransmitters involved with nausea and vomiting.

‘We’ve long known the nausea and vomiting that come along with chemotherapy are a major problem and affect the quality of life of our patients,’ said Powell. ‘The findings of this study, fortunately, provide physicians with a tool to better address the needs of those they are treating for cancer.’
Researchers noted that within the first day after treatment, 74 percent of study participants experienced no nausea or vomiting when their chemotherapy was paired with olanzapine. When a placebo was used instead of olanzapine, that figure dropped to 45 percent. This benefit continued for five days after chemotherapy treatment for many patients.

Sanford Health www.sanfordresearch.org/newsevents/news/NewsDetail25278.cfm?Id=0,1887

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:38:032020-08-26 14:38:21New treatment to prevent nausea, vomiting caused by chemotherapy

Contrast ultrasound identifies deadly liver cancers

, 26 August 2020/in E-News /by 3wmedia

Tiny microbubbles are being used to more effectively identify liver tumours, according to a study. Patients with hepatocellular carcinoma, the third leading cause of cancer deaths worldwide, were found to benefit from contrast-enhanced ultrasound (CEUS) imaging when MRI imaging was inconclusive, according to Dr. Stephanie Wilson, a professor of medicine at the University of Calgary in Canada and Co-President of the International Contrast Ultrasound Society. She said that inconclusive MRIs occur frequently.
‘This is an exciting option because hepatocellular carcinoma is the most common form of liver cancer, and standard imaging with MRI is often an insufficient option for characterizing the tumour,’ Dr .Wilson said.
CEUS uses liquid suspensions of tiny gas microbubbles to improve the clarity and reliability of an ultrasound image without exposing patients to ionizing radiation. The microbubbles are smaller than red blood cells and, when they are injected into a patient’s arm vein, they improve the accuracy of diagnostic ultrasound exams. The microbubbles are expelled from the body within minutes.
David Cosgrove, Emeritus Professor at Imperial and Kings Colleges London, said the findings demonstrate the vast potential benefits of using microbubble ultrasound contrast agents as a safe, convenient and effective diagnostic imaging tool that improves patient care without exposing individuals to ionizing radiation. ‘CEUS is an excellent modality that can help differentiate benign from malignant tumours,’ he added.

International Contrast Ultrasound Society http://tinyurl.com/zms76su

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:38:032020-08-26 14:38:08Contrast ultrasound identifies deadly liver cancers

First patient-based cardiac MRI study using 7T MRI

Cardiology, 26 August 2020/in E-News /by 3wmedia

In a world-first, researchers from Charite – Universitatsmedizin Berlin and the Max Delbruck Centre for Molecular Medicine (MDC) have performed cardiac MRI imaging using a 7T MRI scanner in a patient-based study. 7T MRI imaging is a powerful new technology that allows high resolution images of the beating heart, and has the capability to provide valuable information of the myocardial (heart muscle) tissue structures. Results of the study show that the technology allows the visualizing of very subtle changes of the myocardial tissue structure in patients with abnormal thickening of the heart muscle.
Cardiovascular magnetic resonance imaging (CMR) is turning into a key technology in the diagnosis of myocardial disorders. The method is constantly evolving, and is becoming capable of visualizing both healthy and diseased tissue in increasingly minute detail, even in a heart with normal function. It gives new insights in the heart muscle and assess myocardial damage, including in patients with hypertrophic cardiomyopathy (HCM), a genetically determined abnormal thickening of the heart muscle. 7T MRI imaging is expected to be powerful at visualizing tissue structure at the microscopic scale, including pathological changes and minute depressions. The full capabilities are under evaluation.
In clinical practice, cardiac imaging is performed using 1.5T and 3T MRI scanners. 7T MRI scanners, which constitute a further refinement of the technology, operate at a higher field strength, offering significantly improved resolution as a result. Most of these new scanners remain to be certified for routine clinical use, meaning that their use is limited to research applications; there are currently only five centres in the world capable of visualizing the beating heart using the 7T MRI technology. The biggest challenge of CMR imaging is the heart’s constant movement.
The research group led by Prof. Dr. Jeanette Schulz-Menger, Head of the Experimental and Clinical Research Centre’s (ECRC) Cardiac Outpatient Department. ‘Our aim was to test the potential of 7T MRI scanning in patients with hypertrophic cardiomyopathy, and to test whether the technology is capable of visualizing even the smallest morphological changes,’ explains the cardiologist who specializes in CMR. The researchers succeeded in detecting myocardial crypts’ – minute clefts or fissures which have so far been impossible to visualize in clinical practice in this location.
Their success was made possible as a result of close cooperation with a research group at the MDC’s Berlin Ultrahigh Field Facility (B.U.F.F.), which was led by Prof. Thoralf Niendorf. Together, the researchers compared data obtained from patients with abnormal thickening of the heart muscle who had undergone scanning using both a 7T MRI scanner with 2D CINE imaging and a 3T MRI scanner. The researchers also studied images obtained from healthy volunteers, and using the new generation of MRI scanners.
Following analysis, the researchers concluded that the use of 7T MRI gives new information in patients with hypertrophic cardiomyopathy. ‘In seven out of 13 patients, we were able to adequately visualize minute depressions in the myocardial tissue of the left ventricle,’ says the study’s first author, Dr. Marcel Prothmann. ‘The technology’s high spatial resolution constitutes a massive leap forwards in terms of imaging quality. It allows the precise visualization of structural changes within areas of extensive thickening,’ says Dr. Prothmann. High-resolution imaging may allow us to make more informed diagnoses when faced with a case of heart failure or another type of heart disease.

Charite – Universitatsmedizin Berlin
http://tinyurl.com/hr4b2rj

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:38:032023-09-06 08:21:52First patient-based cardiac MRI study using 7T MRI

Sub-Sensory vibratory noise augments the physiologic complexity of postural control in older adults

, 26 August 2020/in E-News /by 3wmedia

Researchers from the Harvard affiliated Hebrew SeniorLife Institute for Aging Research (IFAR), have published a recent article i which gives evidence that sub-sensory vibrations delivered to the foot sole of older adults significantly augmented the physiologic complexity of postural control and led to improvement in a given mobility assessment. Researchers came to this conclusion by applying vibrating soles to the feet of 12 healthy adults at various sensory thresholds over the course of three visits. After the vibrations were delivered, researchers tested postural sway complexity during eyes open and eyes closed standing assessments. They then evaluated mobility using the timed up and go (TUG) assessment. Findings of the study show that foot sole vibrations at 70 and 85% of sensory threshold increased postural sway complexity. Moreover, these increases correlated with improved TUG times for participants.

When standing, the feet are the only points of contact with the external environment. Therefore, standing postural control is dependent upon the nervous system to detect characteristics of the ground below the foot and deliver that information back to the central nervous system. Vibratory noise increases the sensory input from the foot soles to the postural control system, which leads to greater postural control and improved mobility.

Institute for Aging Researchwww.instituteforagingresearch.org/resources/news

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:38:032020-08-26 14:38:24Sub-Sensory vibratory noise augments the physiologic complexity of postural control in older adults

Researchers identify process that causes chronic neonatal lung disease

, 26 August 2020/in E-News /by 3wmedia

Pediatric researchers at UT Southwestern Medical Center have identified a key component of the pathogenesis of bronchopulmonary dysplasia (BPD), a devastating and sometimes fatal lung disease that affects premature infants. Their findings clarify what prompts the inflammatory response that results in BPD, which previously had been unclear.
The study determined how the NLRP3 inflammasome activates the protein Interleukin 1 beta, which in turn triggers inflammation and development of BPD.
In an animal model of BPD, researchers also tested two FDA-approved drugs that either block the effect of or decrease the production of Interleukin 1 beta and found that these treatments allowed more normal lung development.
Bronchopulmonary dysplasia, a common chronic lung disease in premature infants, develops as a result of the ventilation and oxygen necessary for these infants to survive. Infants born before 30 weeks gestation have immature lungs that lack surfactant, a substance comprised of phospholipids and proteins that is needed for lungs to properly function. This causes premature infants to develop respiratory distress syndrome, requiring the aid of mechanical ventilation. The infants’ exposure to elevated oxygen levels during ventilation activates the process of inflammation that leads to BPD.
‘The same ventilation that ultimately saves their lives, damages their lungs,’ said Dr. Rashmin Savani, Professor and Chief of Neonatal-Perinatal Medicine. ‘Our findings suggest that if we target premature infants born at less than 28 weeks gestation from three to 10 days after birth with this therapy, we might be able to drastically reduce or even eliminate the development of BPD.’ Dr. Savani also holds the William Buchanan Chair in Pediatrics.
Next steps include testing the therapeutic intervention strategies outlined in this study in larger animal models, potentially followed by a Phase 1 clinical trial.

UT Southwestern Medical Center http://tinyurl.com/j2yjrtz

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:38:032020-08-26 14:38:11Researchers identify process that causes chronic neonatal lung disease
Page 166 of 231«‹164165166167168›»

Latest issue of International Hospital

April 2024

4 July 2025

Everdrone expands world-first medical emergency drone network in Sweden

4 July 2025

Wireless implant breakthrough offers personalised chronic pain relief

3 July 2025

EEG-powered brain computer interface enables finger-level robotic hand control

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The medical devices information portal connecting healthcare professionals to global vendors

Sign in for our newsletter
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Media kit
    • Submit Press Release

Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com

PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Sign in for our newsletter

Free subscription